Generics in Australia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Australia
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Australia
Leading company profiles reveal details of key generics market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Australia generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Australia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons to Buy
What was the size of the Australia generics market by value in 2016?
What will be the size of the Australia generics market in 2021?
What factors are affecting the strength of competition in the Australia generics market?
How has the market performed over the last five years?
How large is Australia's generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Australian generics market is forecast to generate total revenues of $1.2bn in 2016, representing a compound annual rate of change (CARC) of -0.5% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 3.2% between 2012 and 2016, to reach a total of 51.4% of total pharma volume in 2016.
Current pricing policy means that many companies are operating below cost in this market, leading to overall decline in the historic period.
Market value forecast
Market volume forecast
Market value forecast
Market volume forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
Aspen Pharmacare Holdings Ltd
Teva Pharmaceutical Industries Limited
Figure 1: Australia generics market value: $ billion, 2012-16(e)
Figure 2: Australia generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Australia generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Australia generics market value forecast: $ billion, 2016-21
Figure 5: Australia generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Australia, 2016
Figure 7: Drivers of buyer power in the generics market in Australia, 2016
Figure 8: Drivers of supplier power in the generics market in Australia, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Australia, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Australia, 2016
Figure 12: Aspen Pharmacare Holdings Ltd: revenues & profitability
Figure 13: Aspen Pharmacare Holdings Ltd: assets & liabilities
Figure 14: Mylan Inc.: revenues & profitability
Figure 15: Mylan Inc.: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Table 1: Australia generics market value: $ billion, 2012-16(e)
Table 2: Australia generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Australia generics market geography segmentation: $ billion, 2016(e)
Table 4: Australia generics market value forecast: $ billion, 2016-21
Table 5: Australia generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Aspen Pharmacare Holdings Ltd: key facts
Table 7: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 8: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 9: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 10: Mylan Inc.: key facts
Table 11: Mylan Inc.: key financials ($)
Table 12: Mylan Inc.: key financial ratios
Table 13: Teva Pharmaceutical Industries Limited: key facts
Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
Table 15: Teva Pharmaceutical Industries Limited: key financial ratios
Table 16: Australia size of population (million), 2012-16
Table 17: Australia gdp (constant 2005 prices, $ billion), 2012-16
Table 18: Australia gdp (current prices, $ billion), 2012-16
Table 19: Australia inflation, 2012-16
Table 20: Australia consumer price index (absolute), 2012-16
Table 21: Australia exchange rate, 2012-16
Single User License:
Corporate User License:
Aspen Pharmacare Holdings Ltd, Mylan Inc., Teva Pharmaceutical Industries Limited
Generics, MarketLine, Australia
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"